Kingscrowd Podcast
SpaceX's highly anticipated IPO is finally here, and Brian Belley and Scott Kitun break down what it means for retail investors. They discuss the performance of pre-IPO vehicles like Republic's mirror tokens, the challenges faced by some secondary market allocations, and why investors should understand the structure behind SPVs, syndicates, and private market access before chasing the next hot IPO. The conversation also explores how investors should think about valuation, long-term conviction, and avoiding emotional decision-making when high-profile companies hit public markets. In the second half, Brian welcomes Teddy Lyons to review Rejuvenate Bio, a gene therapy company focused on aging-related diseases. Teddy explains the company's unique strategy of commercializing animal-health applications first, supported by partnerships with major industry players including Merck Animal Health. The discussion covers the company's technology, revenue opportunities, development milestones, and why Kingscrowd Capital is closely evaluating the deal. Resources Subscribe to free Kingscrowd Newsletter [https://newsletter.kingscrowd.com/subscribe] View Rejuvenate Bio's deal [https://kingscrowd.com/rejuvenate-bio-on-wefunder-2026/] on Kingscrowd Become a Kingscrowd Member [https://kingscrowd.com/register/free/] Chapters 00:00 Intro & Today's Topics 00:38 SpaceX IPO Takes Over the Market 01:01 Who Won From SpaceX Pre-IPO Investing? 03:09 Is SpaceX Overvalued or a Trillion-Dollar Opportunity? 05:24 Why Scott Thinks Investors Need Patience 08:31 IPO Mechanics Explained 12:44 Building an Investment Plan Before Buying 18:18 Mirror Tokens, Republic & Retail Access 21:19 Binance Allocation Problems & Counterparty Risk 23:04 The Future of Secondary Markets 28:08 How to Evaluate SPVs and Syndicates 31:37 Rejuvenate Bio Deal Review Begins 32:31 What Rejuvenate Bio Actually Does 34:35 Why Animal Health Comes First 37:19 Merck Animal Health Partnership Explained 38:20 The Cost Advantage in Gene Therapy 40:17 Brian's Questions & Investment Risks 45:44 Potential Exit Opportunities 49:23 Final Thoughts on Rejuvenate Bio 50:42 Wrap-Up
71 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Kingscrowd Podcast community!